Us2.v1
Us2.ai
Information source:
Vendor
Last updated: December 4, 2024 |
General Information
General | |
---|---|
Product name | Us2.v1 |
Company | Us2.ai |
Subspeciality | Cardiac |
Modality | Ultrasound |
Disease targeted | Heart disease, Pulmonary Hypertension |
Key-features | Automated measurements include 2-dimensional (cardiac volumes, all 4 chambers of the heart), M-mode (e.g. tricuspid annular plane systolic excursion), spectral Doppler (blood flow across all valves, both PW and CW measurements) and tissue Doppler |
Suggested use | During: perception aid (prompting all abnormalities/results/heatmaps), report suggestion |
Technical Specifications
Data characteristics | |
---|---|
Population | Vast majority of adult transthoracic echocardiograms. Not intended for reporting measurements associated with valve disease, pericardial disease, or right-sided hemodynamics (e.g. estimated pulmonary artery systolic pressure); intra-cardiac lesions (e.g. tumours, thrombi); and will not report measurements for complex adult congenital heart disease. |
Input | Transthoracic echocardiography |
Input format | DICOM |
Output | Patient report, editable image annotations, comparison to international reference guidelines |
Output format | DICOM SR, PDF, CSV |
Technology | |
Integration | Integration in standard reading environment (PACS), Integration CIS (Clinical Information System), Integration via AI marketplace or distribution platform, Stand-alone third party application, Stand-alone webbased |
Deployment | Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based, Hybrid solution |
Trigger for analysis | Automatically, right after the image acquisition, On demand, triggered by a user through e.g. a button click, image upload, etc. |
Processing time | 1 - 10 minutes |
Regulatory
Certification | |
---|---|
CE |
Certified,
Class IIb
, MDR
|
FDA | 510(k) cleared , Class II |
Intended Use Statements | |
Intended use (according to CE) | Us2.v1 is a software platform that automatically processes, analyses and makes measurements on acquired transthoracic cardiac ultrasound images, producing a full report with measurements of several key cardiac structural and functional parameters. The data produced by this software is intended to be used to support qualified cardiologists, sonographers, or other licensed professional healthcare practitioners for clinical decision- making. Us2.v1 is indicated for use in adult patients. Us2.v1 has not been validated for the assessment of congenital heart disease, valve disease, pericardial disease, and/or intra- cardiac lesions (e.g. tumours, thrombi). |
Market
Market presence | |
---|---|
On market since | 06-2022 |
Distribution channels | Blackford, Aidoc aiOS, Viz Platform, Eureka Clinical AI, Nuance PIN |
Countries present (clinical, non-research use) | USA, Canada, EU, Australia, New Zealand, Singapore |
Paying clinical customers (institutes) | |
Research/test users (institutes) | |
Pricing | |
Pricing model | Subscription |
Based on | Number of analyses |
Evidence
Evidence | |
---|---|
Peer reviewed papers on performance |
|
Non-peer reviewed papers on performance | |
Other relevant papers |
|